Multiple myeloma is the most common primary bone cancer.
It accounts for 1% of all cancers. It occurs in about 20,000 people in the US each year.
http://orthoinfo.aaos.org/topic.cfm?topic=a00086 published Jan 2011
Table of contents
- Multiple myeloma: Mean Vitamin D level = 5 ng - Dec 2020
- Far better MM survival when getting just 10,000 IU of Vitamin D per WEEK - Oct 2015
- Multiple myeloma 5.3 X more likely in Afgans with a poor Vitamin D Receptor
- Multiple myeloma 2 X more likely if poor Vitamin D Receptor - May 2019
- Multiple myeloma more common in areas with low UVB (Vitamin D) - 2014
- MM: Vitamin D is low, supplementation helps - Nov 2015
- Cancer pain reduced by Vitamin D suplementation - April 2016
- Less Opiod use by patients with higher level of Vitamin D - May 2015
- See also VitaminDWiki
- Wikipedia on Multiple Myeloma
- See also web
Serum Levels of Vitamin D in Patients with Multiple Myeloma
Folia Med (Plovdiv) . 2020 Dec 31;62(4):730-735. doi: 10.3897/folmed.62.e50321
Discusses better response to treatment if have higher level of vitamin D
.  Download the PDF from VitaminDWiki
Prevalence, Supplementation, and Impact of Vitamin D Deficiency in Multiple Myeloma Patients.
Cancer Invest. 2015 Oct 27:1-5. [Epub ahead of print]
Group given the most vitamin D had the best survival
However, results were not statistically significant (too small of study)
Note: Dose size was only about 10,000 IU per WEEK - which they realized at the end of the study was far too little
Lauter B1, Schmidt-Wolf IG1.
1a Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn , Bonn , Germany.
Here, we studied 83 unselected multiple myeloma patients from December 2007 through December 2014.
- Lower 25(OH) D levels (<10 ng/mL) were associated with higher number of plasma cells in the bone marrow.
Supplementation of vitamin D was accompanied with a significant increase in
- hemoglobin (11.8 to 12.3 p = .039),
- leukocyte (4.9 to 5.8 p = .011), and
- erythrocyte (3.8 to 4.0 p = .004) levels,
while thrombocytes (200.5 to 175.2 p = .036) decreased.
In conclusion, the present study found a high incidence of vitamin D deficiency and insufficiency in MM patients. In myeloma patients, vitamin D levels and supplementation should be more widely taken into account.
Download the PDF from VitaminDWiki
Role of vitamin D receptor (VDR) polymorphisms in susceptibility to multiple myeloma in ethnic Kashmiri population
Blood Cells Mol Dis. 2013 Jun;51(1):56-60. doi: 10.1016/j.bcmd.2013.02.001.
Syed Shafiaa, Iqbal Qasima, Sheikh Aejaz Azizb, Imtiyaz A. Bhata, Syed Nisarb, Zafar Amin Shaha, , ,
Background: Vitamin D regulates many biological processes including bone metabolism, innate immune response, and cell proliferation and differentiation by binding to its receptor VDR. Vitamin D receptor (VDR) gene polymorphisms have been associated with many cancers like breast, colorectal, prostate, and skin. The main aim of this study was to determine whether VDR polymorphisms (ApaI, BsmI and FokI) are associated with increased risk of multiple myeloma.
Methods: We designed a case control study where 75 multiple myeloma cases were studied for VDR polymorphisms (ApaI, BsmI and FokI) against 150 controls taken from general population. The polymorphisms of VDR gene were investigated using PCR–RFLP method.
Results: We did not find any significant association between ApaI and BsmI polymorphisms and multiple myeloma risk (P > 0.05), but FokI polymorphism was significantly associated with increased risk for multiple myeloma. We also found a significant association between the ff variant genotype with creatinine levels, albumin levels, and Durie–Salmon stage III.
Conclusion: Our findings suggest that the FokI polymorphism is involved in the increased susceptibility to development and progression in multiple myeloma in the ethnic Kashmiri population. Furthermore these results suggest that ff genotype is associated with higher risk for developing multiple myeloma.
PDF (which has the 5.3 X factor) can be rented at DeepDyve
See Vitamin D Receptor in VitaminDWiki
29 health problems are greatly increased if poor VDR
Are low ultraviolet B and vitamin D associated with higher incidence of multiple myeloma?
J Steroid Biochem Mol Biol. 2015 Apr;148:245-52. doi: 10.1016/j.jsbmb.2014.12.005. Epub 2014 Dec 10.
Mohr SB1, Gorham ED1, Garland CF2, Grant WB3, Garland FC1, Cuomo RE4.
1Deartment of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, United States; Naval Health Research Center, San Diego, CA, United States.
2Deartment of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, United States.
3Sunlight, Nutrition, and Health Research Center, San Francisco, CA, United States.
4Deartment of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, United States; Graduate School of Public Health, San Diego State University, San Diego, CA, United States. Electronic address: raphael.e.cuomo at gmail.com.
The purpose of this study was to determine whether an inverse association exists between latitude, solar ultraviolet B (UVB) irradiance, and incidence rates of multiple myeloma.
Methods Associations of latitude and UVB irradiance with age-standardized incidence rates of multiple myeloma were analyzed for 175 countries while controlling for sex-specific obesity prevalence, cigarette consumption, and alcohol consumption using multiple linear regression.
Results Incidence rates of multiple myeloma were greater at higher latitudes (R(2) for latitude for males=0.31, p<0.0001; females R(2)=0.27, p<0.0001). In regression models for males (R(2)=0.62, p<0.0001) and females (R(2)=0.51, p<0.0001), UVB irradiance was independently inversely associated with incidence rates.
Conclusions Age-adjusted incidence rates of multiple myeloma were higher in countries with lower solar UVB irradiance. Further investigation is warranted in individuals of the association of prediagnostic serum 25(OH)D with risk.
PMID: 25500072 DOI: 10.1016/j.jsbmb.2014.12.005
MM prevelance after correction for age
PDF is available at DeepDyve
Prevalence of Vitamin D Deficiency in Patients with Bone Metastases and Multiple Myeloma.
Anticancer Res. 2015 Nov;35(11):6281-5.
Maier GS1, Horas K2, Kurth AA3, Lazovic D4, Seeger JB5, Maus U4.
1 University Hospital of Orthopaedic Surgery, Pius-Hospital, Carl-von-Ossietzky-University, Oldenburg, Germany gerrit.maier at uni-oldenburg.de.
2 ANZAC Research Institute, University of Sydney at Concord, Sydney, NSW, Australia.
3 Department of Orthopaedic Surgery, Themistocles Gluck Hospital, Ratingen, Germany.
4 University Hospital of Orthopaedic Surgery, Pius-Hospital, Carl-von-Ossietzky-University, Oldenburg, Germany.
5 Department of Orthopaedic Surgery, Justus-Liebig-University, Giessen, Germany.
BACKGROUND/AIM: Breast and prostate cancer are amongst the most prevalent malignancies globally and up to 40% of patients will develop metastatic disease, particularly to the skeleton. Multiple myeloma is the most common cancer to affect bone with up to 90% of patients developing bone lesions. Although several studies demonstrated that endocrine changes such as vitamin D deficiency promote secondary cancer growth in bone, relatively few have reported its prevalence. For this reason, the purpose of the present study was to evaluate the prevalence of hypovitaminosis D in patients with bone metastases and multiple myeloma.
PATIENTS AND METHODS: Serum 25-OH-D levels of patients with metastatic bone disease were measured on admission. Statistical analyses was performed to evaluate for possible confounders of hypo-vitaminosis D.
RESULTS: We found a widespread and alarming rate of vitamin D deficiency in patients with metastatic bone disease and multiple myeloma. Of note, patients with bone metastases due to breast cancer, prostate cancer and multiple myeloma rarely reached sufficient serum 25-OH-D levels.
CONCLUSION: It is of utmost clinical importance to assess vitamin D levels in cancer patients, especially in those with, or at high risk of developing metastatic bone disease.
(Reduced palliative cancer pain after Vitamin D supplementation – April 2016)
- Blood cell cancer is associated with a 3X worse Vitamin D Receptor – June 2019
- Overview Cancer and vitamin D has the following chart
- Multiple myeloma develops in 6.1 per 100,000 people per year
- 2nd most common hematological malignancy in the U.S.
- The five year survival rate is 45%.(with treatment, 6 months if no treatment)
- Is twice as common in African Americans (who have low levels of vitamin D) as it is in White Americans
- Bone pain affects almost 70% of patients and is the most common symptom
- A Retrospective Analysis of the Prevalence and Clinical Outcomes of Vitamin D Deficiency in Myeloma Patients in Tropical Australia - March 2020 - DOI: 10.1007/s00520-019-04942-7,"Patients with vitamin D deficiency had a higher likelihood of peripheral neuropathy compared with their non-vitamin D counterparts (73% vs. 33%, P = 0.03)"
- Vitamin D Receptor Gene Polymorphism Is Associated With Multiple Myeloma" Jan 2020, DOI: 10.1002/jcb.29135 3X more likely to have a poor Vitamin D Receptor
There have actually been
|4371 visitors, last modified 09 Jan, 2021,
|14837||MM Dec 2020.pdf||PDF 2020||admin 09 Jan, 2021 18:49||398.23 Kb||133|
|7995||MM smile.jpg||admin 17 May, 2017 01:02||59.35 Kb||3329|
|7136||MM Males.jpg||admin 02 Oct, 2016 15:39||36.18 Kb||588|
|7014||MM survival.jpg||admin 25 Aug, 2016 13:05||16.55 Kb||3865|
|7013||Multiple Myeloma.pdf||admin 25 Aug, 2016 13:05||599.02 Kb||959|